Study on the effect of reducing agents on nicotine residues in smoker plasma sample
Not Applicable
Completed
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
1. Chronic smoker
2. patients above 18 years old
3. consumer of other tobacco products such as chewed products, electronic cigarette, etc.
Exclusion Criteria
1. Patients with no smoking effect
2. Pregnant women
3. Patients taken alcohol within 24 hours
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms enable reducing agents to reverse cotinine to nicotine in CTRI/2022/12/048600 plasma samples?
How do reducing agents in CTRI/2022/12/048600 compare to standard nicotine detection methods in smokers?
Which plasma biomarkers correlate with successful cotinine reversion using reducing agents in smokers?
What are the potential adverse effects of reducing agents on plasma sample stability in nicotine metabolism studies?
Are there synergistic compounds or combination strategies that improve cotinine-to-nicotine conversion in vitro?